Reviewing Intellia Therapeutics (NASDAQ:NTLA) and NutraLife Biosciences (OTCMKTS:NLBS)

Intellia Therapeutics (NASDAQ:NTLA) and NutraLife Biosciences (OTCMKTS:NLBS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Valuation and Earnings

This table compares Intellia Therapeutics and NutraLife Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67 million	26.10	-$412.69 million	($3.83)	-3.90
NutraLife Biosciences	N/A	N/A	N/A	($0.02)	N/A

NutraLife Biosciences has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than NutraLife Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intellia Therapeutics and NutraLife Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-609.85%	-56.81%	-45.34%
NutraLife Biosciences	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and target prices for Intellia Therapeutics and NutraLife Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	2	8	9	1	2.45
NutraLife Biosciences	0	0	0	0	0.00

Intellia Therapeutics currently has a consensus price target of $19.59, indicating a potential upside of 31.04%. Given Intellia Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than NutraLife Biosciences.

Insider & Institutional Ownership

88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.1% of Intellia Therapeutics shares are owned by insiders. Comparatively, 34.6% of NutraLife Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Intellia Therapeutics beats NutraLife Biosciences on 6 of the 11 factors compared between the two stocks.

About Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

About NutraLife Biosciences

NutraLife BioSciences, Inc., together with its subsidiaries, engages in the development, manufacture, and distribution of nutraceutical, dietary, wellness, and cannabidiol (CBD) products. Its CBD products include cannabinoid-rich hemp oil derived from industrial hemp; tinctures; topical lotions and oils applied directly to the skin to treat pain or inflammation; face creams; massage oils; nutraceutical sprays with CBD as an added ingredient; and pet products. The company also offers other products, such as skincare and sanitizer products. NutraLife BioSciences, Inc. sells its products through nutralifebiosciences.com, as well as through private label distributors, online retailers, and retail outlets. The company was formerly known as NutraFuels, Inc. and changed its name to NutraLife BioSciences, Inc. in March 2019. NutraLife BioSciences, Inc. was incorporated in 2010 and is based in Coconut Creek, Florida.